Head to Head Contrast: BG Medicine (OTCMKTS:BGMD) vs. Cencora (NYSE:COR)

BG Medicine (OTCMKTS:BGMD) and Cencora (NYSE:COR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for BG Medicine and Cencora, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
Cencora	0	3	9	0	2.75

Cencora has a consensus target price of $311.25, suggesting a potential upside of 5.20%. Given Cencora’s stronger consensus rating and higher possible upside, analysts plainly believe Cencora is more favorable than BG Medicine.

Profitability

This table compares BG Medicine and Cencora’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
Cencora	0.60%	267.36%	4.31%

Earnings & Valuation

This table compares BG Medicine and Cencora”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
Cencora	$293.96 billion	0.20	$1.51 billion	$9.72	30.44

Cencora has higher revenue and earnings than BG Medicine.

Institutional and Insider Ownership

97.5% of Cencora shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by insiders. Comparatively, 10.8% of Cencora shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

BG Medicine has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500. Comparatively, Cencora has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Summary

Cencora beats BG Medicine on 9 of the 10 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Cencora

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.